1. Home
  2. TNXP vs RDHL Comparison

TNXP vs RDHL Comparison

Compare TNXP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$15.52

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$1.19

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
RDHL
Founded
2007
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.9M
3.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
RDHL
Price
$15.52
$1.19
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$70.00
N/A
AVG Volume (30 Days)
762.6K
1.5M
Earning Date
11-10-2025
09-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,299,000.00
$9,550,000.00
Revenue This Year
$14.79
$381.91
Revenue Next Year
$933.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.62
52 Week Low
$6.76
$1.01
52 Week High
$130.00
$8.75

Technical Indicators

Market Signals
Indicator
TNXP
RDHL
Relative Strength Index (RSI) 40.54 47.12
Support Level $13.70 $1.07
Resistance Level $16.18 $1.07
Average True Range (ATR) 1.22 0.06
MACD 0.22 0.04
Stochastic Oscillator 39.22 70.83

Price Performance

Historical Comparison
TNXP
RDHL

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: